As of 2026-03-17, the Intrinsic Value of Mirum Pharmaceuticals Inc (MIRM) is 23.02 USD. This MIRM valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 92.64 USD, the upside of Mirum Pharmaceuticals Inc is -75.20%.
The range of the Intrinsic Value is 15.64 - 33.30 USD
Based on its market price of 92.64 USD and our intrinsic valuation, Mirum Pharmaceuticals Inc (MIRM) is overvalued by 75.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (307.48) - (94.14) | (142.78) | -254.1% |
| DCF (Growth 10y) | (197.81) - (660.88) | (303.70) | -427.8% |
| DCF (EBITDA 5y) | 15.64 - 33.30 | 23.02 | -75.2% |
| DCF (EBITDA 10y) | 79.61 - 173.63 | 117.79 | 27.2% |
| Fair Value | -4.36 - -4.36 | -4.36 | -104.71% |
| P/E | (7.42) - (8.69) | (8.29) | -108.9% |
| EV/EBITDA | 0.87 - 7.92 | 3.78 | -95.9% |
| EPV | (13.11) - (18.12) | (15.62) | -116.9% |
| DDM - Stable | (3.97) - (17.71) | (10.84) | -111.7% |
| DDM - Multi | (1.20) - (4.29) | (1.89) | -102.0% |
| Market Cap (mil) | 5,589.90 |
| Beta | 0.71 |
| Outstanding shares (mil) | 60.34 |
| Enterprise Value (mil) | 5,603.01 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.40% |
| Cost of Debt | 7.00% |
| WACC | 8.32% |